Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics
about
Clinical effectiveness of dolutegravir in the treatment of HIV/AIDSMultifunctional facets of retrovirus integraseRous sarcoma virus synaptic complex capable of concerted integration is kinetically trapped by human immunodeficiency virus integrase strand transfer inhibitors.Molecular mechanisms of retroviral integration site selection.Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV.The role of dolutegravir in the management of HIV infectionHIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.Dolutegravir for the treatment of adult patients with HIV-1 infection.Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection.The preclinical discovery and development of dolutegravir for the treatment of HIV.Dolutegravir as maintenance monotherapy: first experiences in HIV-1 patients.Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase.Different Pathways Leading to Integrase Inhibitors ResistanceEffects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.Impact of HIV-1 Integrase L74F and V75I Mutations in a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors.Could the "Janus-like" properties of the halobenzene CX bond (X=Cl, Br) be leveraged to enhance molecular recognition?How Polypurine Tract Changes in the HIV-1 RNA Genome Can Cause Resistance against the Integrase Inhibitor Dolutegravir.
P2860
Q26778450-A09AC5AA-2814-46C4-A67F-86634BF6220DQ26795766-7E49ACF9-22F9-437E-B689-0BAE21F12E17Q33888602-062706E3-116B-4638-A61A-FF7263E88607Q34249653-6A586A7B-8256-4670-A970-0FFD1BFE35ACQ34726183-1EE2BEE8-6DBB-424F-BDB7-A833B3F6CF92Q35121450-C02C73A1-D169-4E6A-A24F-23AFFA5F4173Q35134947-6B60B3DF-29C3-43AC-8770-71A51215E277Q38201520-912266A0-2319-4C9C-B909-233D330434C5Q38570500-CD615B1D-A31C-4B76-A014-8992A7731523Q38620489-C3C37316-C086-4CF5-9B5A-F6188E0E6812Q38906639-2970D5D4-42D1-42F8-8A7D-BE26B6456ADEQ38924027-A95A8B92-16BC-4F69-839E-0CE023E55819Q39103603-C9CE1D0F-841F-4554-8037-7D43D7D7A596Q39566226-35E1B350-250B-404F-B260-06B2AAB19ADBQ40190127-C8367D0F-0FEF-4B31-9012-58FF8D153D7DQ51034290-2F17A4F1-E27E-495D-8747-C6CF3B8EA3ABQ53696676-B4AB8899-96CD-4D5A-8B06-51F7A6CAA3AE
P2860
Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Dolutegravir interactions with ...... ance and dissociation kinetics
@ast
Dolutegravir interactions with ...... ance and dissociation kinetics
@en
Dolutegravir interactions with ...... ance and dissociation kinetics
@nl
type
label
Dolutegravir interactions with ...... ance and dissociation kinetics
@ast
Dolutegravir interactions with ...... ance and dissociation kinetics
@en
Dolutegravir interactions with ...... ance and dissociation kinetics
@nl
prefLabel
Dolutegravir interactions with ...... ance and dissociation kinetics
@ast
Dolutegravir interactions with ...... ance and dissociation kinetics
@en
Dolutegravir interactions with ...... ance and dissociation kinetics
@nl
P2093
P2860
P1433
P1476
Dolutegravir interactions with ...... ance and dissociation kinetics
@en
P2093
Felix DeAnda
Kazunari Hattori
Kendra E Hightower
Mark R Underwood
Robert T Nolte
Takashi Kawasuji
Tomokazu Yoshinaga
P2860
P304
P356
10.1371/JOURNAL.PONE.0077448
P407
P577
2013-01-01T00:00:00Z